PharmaTelevision - Marco Boorsma describes Forbion Capital Partners’ investment strategy and gives his personal perspective on the future of the Biotech sector

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Marco Boorsma describes Forbion Capital Partners’ investment strategy and gives his personal perspective on the future of the Biotech sector

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Marco Boorsma, Senior Analyst at Forbion

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Types of investments

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe in Milan, in spring 2011. On this show I have Marco Boorsma , who is a Principal at Forbion Capital Partners based in Holland, welcome to the show.

Marco Boorsma:

Thank you Fintan.

Fintan Walton:

Forbion Capital Partners came out of I understand ABN AMRO originally, tell us little bit about the history of Forbion Capital Partners and the types of investments your business does?

Marco Boorsma:

Yes, well first of all thank you for having me here. Yes as you said there rightfully Forbion spun out from ABN AMRO in back in 2006 it was actually the team that is now Forbion is pretty much was before at ABN AMRO doing the same type of investments as we do right now, so life science investments, biotechnology drug development and medical devices, I will get to that in a bit more detail later on. So the team got the opportunity to take the portfolio with a 200 million front in total into Forbion Capital Partners and just continue the business as it is as ABN AMRO but then as a standalone French capital with Coller Capital and ABN AMRO as the main shareholders at that time and that was then the secondary then defined for us to two other LPs.

Fintan Walton:

Okay, and since it was spun out of ABN AMRO has it raised new money as well for it's some for new funds?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Marco Boorsma

Senior Analyst

Marco Boorsma , is Principal at Forbion and joined the team in 2007 as Analyst. Before joining Forbion Marco Boorsma was Business Development Director at DSM Pharmaceutical Products, responsible for out-licensing of biomanufacturing technology and securing and managing contract manufacturing projects. Prior to that Marco Boorsma was project manager and scientist responsible for process development and cGMP manufacturing of biopharmaceuticals. While at Cytos Biotechnology (Switzerland) Marco Boorsma developed several cell lines and processes for high-value biosimilar proteins. At Forbion Marco Boorsma is responsible for the investment process from scouting and analyzing new opportunities to the investment itself. He also provides market and trend analyses supporting Forbion 's business strategy. Marco Boorsma is Observer to the Board of Cardoz AB and Exosome Diagnostics. After obtaining a master's degree in molecular biology from the University of Groningen, he received his PhD in biotechnology from the ETH Institute for Technology in Zurich, Switzerland for his work on virus-based gene expression systems. Marco executed his work in the groups of Prof. James Bailey and Prof. Ari Helenius at the ETH, and at the Laboratory of Molecular Biology of the Medical Research Counsel in Cambridge, UK.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Forbion Capital Partners

Forbion Capital Partners invest in Life Sciences and Biomedical Technology companies developing world-class drugs and technologies, with a clear focus on product development. The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs and focuses on companies that have innovative technologies and drug development programs with unique advantages over current treatments. Furthermore, Forbion invest in medical device companies with a focus on interventional cardiology and gastroenterology. The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners . Throughout this time the Forbion team made new investments and has successfully divested from a series of companies. Current assets under management exceed EUR 350M, split between three active funds and comprising some 24 promising portfolio companies. Forbion co-manages BioGeneration Ventures, an early stage-stage fund focused on academic spin-outs and seed investments in the Netherlands. Forbion Capital Partners has offices in Naarden, The Netherlands, and Munich, Germany.